

§ 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

***Amendments***

***In the Claims:***

Please cancel claim 4 without prejudice or disclaimer.

Please substitute the following claim 1 for the pending claim 1:

- a'
1. (Once amended) A method for killing neoplastic cells, said method comprising:
- (a) delivering into said neoplastic cells a vector for gene delivery, said vector comprising a nucleotide molecule encoding folypolyglutamyl synthetase (FPGS), wherein said nucleotide molecule directs the production of said FPGS in said neoplastic cells containing said nucleotide molecule;
  - (b) treating said neoplastic cells containing said nucleotide molecule with an antifolate drug; and
  - (c) killing said neoplastic cells containing said nucleotide molecule.

[Please substitute the following claim 2 for the pending claim 2:]

2. (Once amended) The method of claim 1, wherein said FPGS is a mammalian FPGS.

Q<sup>1</sup> [Please substitute the following claim 3 for the pending claim 3:]

3. (Once amended) The method of claim 2, wherein said mammalian FPGS is a human FPGS.

Please substitute the following claim 5 for the pending claim 5:

Q<sup>2</sup> 5. (Once amended) The method of claim 1, wherein said antifolate drug is methotrexate, edatrexate, aminopterin, or a thymidylate synthetase inhibitor.

Please substitute the following claim 11 for the pending claim 11:

Q<sup>3</sup> 11. (Once amended) The method of claim 1, wherein said vector for gene delivery is a prokaryotic vector, a cationic liposome, a fusogenic liposome, a DNA-adenovirus conjugate, a DNA-protein complex, a non-viral T7 autogene vector, a starburst polyamidoamine dendrimer, a cationic peptide, a mammalian artificial chromosome, an endothelial cell, or a macrophage.

Please add the following claims:

Q<sup>4</sup> 12. (New) The method of claim 11, wherein said vector for gene delivery is a prokaryotic vector.

13. (New) The method of claim 1, wherein the vector for gene delivery is delivered into said neoplastic cells by direct injection of nucleic acid, particle-mediated gene transfer, or receptor-mediated gene transfer.